Nedaplatin: a cisplatin derivative in cancer chemotherapy

Figures & data

Figure 1 Platinum agents (cisplatin, nedaplatin, and carboplatin).

Figure 2 Postulated pathway for hydrolysis and DNA binding of nedaplatin.

Figure 3 Observed AUC and dose of nedaplatin (mg/m²).

Abbreviation: AUC, area under the curve.

Figure 4 Observed AUC and clearance.

Note: There was favorable correlation between observed AUC and dose normalized by creatinine clearance.

Abbreviation: AUC, area under the curve.

Figure 5 Predictive AUC and observed AUC.

Note: Predictive AUC was correlated with the observed AUC.

Abbreviations: AUC, area under the curve; ME, mean prediction error as a measure of bias; RMSE, root mean squared error as a measure of precision.

Figure 6 Observed AUC and relative reduction rate of platelet.

Notes: There was a relationship between the observed AUC and rate of decrease in platelets (PLT). Five patients, who were circled in figure, underwent concurrent chemoradiotherapy and showed unexpectedly grade 4 thrombocytopenia, and the predicted PLT did not follow the regression line.

Abbreviations: PLT_nadir, the nadir of platelets count after nedaplatin administration; PLT_pre, the platelets count before nedaplatin administration; AUC, area under the curve; SD, standard deviation.

Table 1 Phase II studies of nedaplatin

Author	Numbers	Line of chemotherapy	Regimen	Response rate
Non-small cell lung cancer
Teramoto et al^Citation18	44	First-line	DTX/NDP	50.0%
Hirose et al^Citation19	47	First-line	Weekly PTX/NDP	53.2%
Oshita et al^Citation20	38	First-line	CPT-11/NDP	65.8%
Oshita et al^Citation21	28	First-line	CPT-11/NDP then gefinitib	42.9%
Esophageal cancer
Cao et al^Citation30	46	First-line	PTX/NDP	41.7%
Gong et al^Citation31	49	First-line	PTX/NDP	43.6%
Guo et al^Citation32	43	First-line	DTX/NDP/5-FU	62.8%
Jingu et al^Citation34	30	First-line	CCRT with NDP/5-FU	73.3%
Uterine cervical cancer
Takekuma et al^Citation39	50	First/second-line	PTX/NDP	44.4%
Yamaguchi et al^Citation40	68	First-line	CPT-11/NDP	75.8%
Tsuda et al^Citation41	27	First-line	CPT-11/NDP	59.0%
Yokoyama et al^Citation44	45	First-line	CCRT with weekly NDP	88.9%
Head and neck cancer
Ohashi et al^Citation49	31	First-line	CCRT with S-1/NDP	81.0%
Kurita et al^Citation56	30	First-line	DTX/NDP	33.3%
Urothelial cancer
Kitamura et al^Citation55	45	Second-line	PTX/IFM/NDP	40.0%
Shinohara et al^Citation53	32	Second-line	PTX/IFM/NDP	75.0%

Abbreviations: DTX, docetaxel hydrate; NDP, nedaplatin; PTX, paclitaxel; CPT-11, irinotecan hydrochloride hydrate; 5-FU, fluorouracil; CCRT, concurrent chemoradiotherapy; S-1, tegafur, gimeracil, oteracil potassium; IFM, ifosfamide.

TeramotoKAsadaYOzakiYA phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancerCancer Chemother Pharmacol201270453153722864949

 PubMed Web of Science ®Google Scholar

HiroseTSugiyamaTKusumotoSPhase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancerAnticancer Res20092951733173819443395

 PubMed Web of Science ®Google Scholar

OshitaFYamadaKSaitoHNodaKHamanakaNIkeharaMPhase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancerJ Exp Ther Oncol20044434334815844664

 PubMedGoogle Scholar

OshitaFYamadaKSaitoHNodaKPhase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancerCancer Chemother Pharmacol200862346547017960380

 PubMed Web of Science ®Google Scholar

CaoWXuCLouGA phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancerJpn J Clin Oncol200939958258719509000

 PubMed Web of Science ®Google Scholar

GongYRenLZhouLPhase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinomaCancer Chemother Pharmacol200964232733319048253

 PubMed Web of Science ®Google Scholar

GuoJFZhangBWuFA phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinomaChin J Cancer201029332132420193118

 PubMedGoogle Scholar

JinguKMatsushitaHTakedaKLong-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II studyBMC Cancer20121254223171077

 PubMed Web of Science ®Google Scholar

TakekumaMHirashimaYItoKPhase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group studyGynecol Oncol2012126334134522609108

 PubMed Web of Science ®Google Scholar

YamaguchiSNishimuraRYaegashiNPhase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065)Oncol Rep201228248749322614251

 PubMed Web of Science ®Google Scholar

TsudaHHashiguchiYNishimuraSPhase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancerBr J Cancer20049161032103715292935

 PubMed Web of Science ®Google Scholar

YokoyamaYTakanoTNakaharaKA phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit StudyOncol Rep20081961551155618497964

 PubMed Web of Science ®Google Scholar

OhashiTOhnishiMTanahashiSMuraiMEfficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancerJpn J Clin Oncol201141334835221109512

 PubMed Web of Science ®Google Scholar

KuritaHYamamotoENozakiSMulticenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinomaCancer Chemother Pharmacol201065350350819579024

 PubMed Web of Science ®Google Scholar

KitamuraHTaguchiKKunishimaYPaclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC groupCancer Sci201110261171117521323791

 PubMed Web of Science ®Google Scholar

ShinoharaNHarabayashiTSuzukiSSalvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapyCancer Chemother Pharmacol200658340240716416335

 PubMed Web of Science ®Google Scholar